With some biologic medicines topping $4 million for a single dose, specialty medicines now account for 46% of pharmaceutical spending—despite making up only 2% of prescriptions. Biosimilars, which deliver, on average, 50% in cost savings with some exceeding 90%, represent an underutilized solution with major potential.

This webinar explores how to unlock that potential using the new National Alliance Biosimilars Toolkit, along with real-world examples of organizations successfully leveraging biosimilars to significantly reduce medical and pharmacy spend—without compromising patient care. Register here.